TY - JOUR T1 - Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic JF - Frontline Gastroenterology JO - Frontline Gastroenterol SP - 89 LP - 90 DO - 10.1136/flgastro-2020-101760 VL - 13 IS - 1 AU - John McGoran AU - Alan Wilson AU - Shannan McErlain AU - Noreen Kennedy AU - Caroline Masterson AU - Caroline Collins AU - Graham Morrison Y1 - 2022/01/01 UR - http://fg.bmj.com/content/13/1/89.abstract N2 - Promising evidence in the subcutaneous (SC) administration of the infliximab (IFX) biosimilar CT-P13 (Remsima) has emerged in recent years. Furthermore, immunogenicity data have suggested superior steady state therapeutic blood levels of IFX and lower rate of anti-IFX antibodies in a cohort of patients receiving SC Remsima following two intravenous induction doses in contrast to their counterparts who continued to receive intravenous therapy.1 2 In response to the challenges posed by the COVID-19 pandemic to patients with inflammatory bowel disease (IBD) receiving IFX, we embarked on a patient-partnered programme in switching to SC Remsima. Seventy-five individuals were included in the preliminary service development and some demographics are outlined in table 1. An assessment of patients’ attitudes was conducted using a survey.View this table:In this windowIn a new windowTable 1 Demographic … ER -